

AMENDMENTS TO THE CLAIMS

1 - 82. (Canceled).

83. (Previously presented) A method for inhibiting immunoglobulin production comprising contacting T-cells with an effective amount of an antibody that binds an antigen that:

(a) is present on activated but not resting T-cells;

(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin fusion protein (CD40-Ig), the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and

(c) is pre-cleared by precipitation with the CD40-Ig;

wherein the antibody blocks binding of the CD40-Ig to activated T-cells and inhibits T-cell induction of B-cell activation.

84. (Previously presented) A method for inhibiting activation of B-cells comprising contacting T-cells with an effective amount of an antibody that binds an antigen that:

(a) is present on activated but not resting T-cells;

(b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin fusion protein (CD40-Ig), the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and

(c) is pre-cleared by precipitation with the CD40-Ig;

wherein the antibody blocks binding of the CD40-Ig to activated T-cells and inhibits T-cell induction of B-cell activation.

